Table 1.
Included bacteria, relevant "old" and "new" drugs, dosages, and costs
| Bacteria name | Estimated number of cases in the US in hospitalized patients (2017) | Old antibiotic drugs | New antibiotic drugs | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug name | Dose | Cost per treatment course (USD)a | Estimated annual cost (USD) | Drug name | Dose | Cost per treatment course (USD)a | Estimated annual cost (USD) | ||
| Vancomycin-resistant Enterococcus faecium (VRE) | 54,500 | Daptomycin |
8-10 mg/kg × 1/day (~ 750 mg × 1/day) |
1093 | 59,544,520 | Omadacycline |
IV: loading 200 mg; Maintenance 100 mg × 1/day O: 300 mg × 1/day |
IV: 6200 PO: 6951 |
IV: 337,900,000 PO: 378,829,500 |
| Linezolid | 600 mg × 2/d | 2188 | 119,226,380 | ||||||
| Tigecycline | Loading: 200 mg; Maintenance: 100 mg × 2/day | 6989 | 380,889,600 | Oritavancin | 1200 mg (Single dose) | 2987 | 162,791,500 | ||
| Telavancin |
10 mg/kg × 1/day (~ 750 mg × 1/day) |
8595 | 468,443,850 | ||||||
| Methicillin-resistant Staphylococcus aureus (MRSA) | 323,700 | Vancomycin | 15 mg/kg × 2/day (~ 1 gr × 2/day) | 115 | 37,225,500 | Ceftaroline | 600 mg × 2/day | 6778 | 2,194,038,600 |
| Daptomycin |
8-10 mg/kg × 1/day (~ 750 mg × 1/day) |
1093 | 353,804,100 | Dalbavancin |
1,000 mg (single dose) + 500 mg (1 week later) |
5691 | 1,842,176,700 | ||
| Linezolid | 600 mg × 2/d | 2188 | 708,255,600 | Oritavancin | 1200 mg (Single dose) | 2987 | 966,891,900 | ||
| Telavancin | 10 mg/kg × 1/day (~ 750 mg × 1/day) | 8595 | 2,782,201,500 | Tedizolid | 200 mg × 1/day | 5170 | 1,673,529,000 | ||
| Lefamulin |
IV: 150 mg × 2/day PO: 600 mg × 2/day |
IV: 3444 PO: 4620 |
IV: 1,114,822,800 PO: 1,495,494,000 |
||||||
| Delafloxacin |
IV: 300 mg × 2/day PO: 450 mg × 2/day |
IV: 4452 PO: 2380 |
IV: 1,441,112,400 PO: 770,406,000 |
||||||
| Omadacycline |
IV: loading 200 mg, maintenance 100 mg × 1/day PO: 300 mg × 1/day |
IV: 6200 PO: 6951 |
IV: 2,006,940,000 PO: 2,250,038,700 |
||||||
| Carbapenem-resistant Enterobacterales | 13,100 | Meropenem | 2 g × 3/day | 717 | 9,392,700 | Ceftazidime-avibactam | 2.5 g × 3/day | 18,084 | 236,900,400 |
| Colistimethate | Loading: 9 MU (~ 300 mg); Maintenance: 4.5 MU × 2/day (~ 150 mg × 2/day) | 941 | 12,327,100 | Meropenem-Vaborbactam | 4 g × 3/day | 16,632 | 217,879,200 | ||
| Amikacin | 15 mg/kg × 1/day (~ 1 gr × 1/day) | 260 | 3,406,000 | Cilastatin / Imipenem / Relebactam |
1.25 g × 4/day |
17,976 | 235,485,600 | ||
| Gentamicin | 240 mg × 1/day | 44 | 576,400 | Cefiderocol | 2 g × 3/day | 18,480 | 242,088,000 | ||
| Tigecycline |
Loading: 200 mg once; Maintenance: 100 mg × 2/day |
6989 | 91,555,900 | Eravacycline |
1 mg/kg × 2/day (~ 100 mg × 2/day) |
3293 | 43,138,300 | ||
| Plazomicin | 15 mg/kg × 1/day (~ 1000 mg × 1/day) | 10,584 | 138,650,400 | ||||||
| Carbapenem-resistant Acinetobacter baumannii (CRAB) | 8500 | Colistimethate |
Loading: 9 MU (~ 300 mg); Maintenance: 4.5 MU × 2/day (~ 150 mg × 2/day) |
941 | 7,998,500 | Cefiderocol | 2 g × 3/day | 18,480 | 157,080,000 |
| Minocycline | 100 mg × 2/day | 5448 | 46,308,000 | ||||||
| Tigecycline |
Loading: 200 mg once; Maintenance: 100 mg × 2/day |
6989 | 59,406,500 | ||||||
| Meropenem | 2 g × 3/day | 717 | 6,094,500 | ||||||
|
Multidrug-resistant Pseudomonas aeruginosa |
32,600 | Gentamicin | 240 mg × 1/day | 44 | 30,676,600 | Ceftazidime-avibactam | 2.5 g × 3/day | 18,084 | 589,538,400 |
| Amikacin | 15 mg/kg × 1/day (~ 1 gr × 1/day) | 260 | 8,476,000 | Ceftolozane-tazobactam |
HAP/VAP: 3 g × 3/day UTI: 1.5 g × 3/day |
HAP/VAP: 12,628 UTI: 6314 |
HAP/VAP: 411,672,800 UTI: 205,836,400 |
||
| Colistimethate |
Loading: 9 MU (~ 300 mg); Maintenance: 4.5 MU × 2/day (~ 150 mg × 2/day) |
941 | 1,434,400 | Cefiderocol | 2 g × 3/day | 18,480 | 602,448,000 | ||
| Cilastatin / Imipenem / Relebactam |
1.25 g × 4/day |
17,976 | 586,017,600 | ||||||
HAP Hospital-acquired pneumonia, IV intravenous, PO Pers. ob., UTI urinary tract infection, VAP ventilator-associated pneumonia
aAll treatment costs were calculated for a 14-day treatment course, unless mentioned otherwise